Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 16/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24137829 | 0.91 | PRMT5 (0.43) | ELANEPRMT5WDR77F2PLAU | |
| SCHEMBL15077317 | 0.87 | PRMT5 (0.43) | PRMT5WDR77F2AAK1 | |
| SCHEMBL25935774 | 0.85 | PRMT5 (0.42) | PRMT5WDR77F2AAK1 | |
| SCHEMBL152838 | 0.85 | PRMT5 (0.45) | ELANEPRMT5WDR77F2AAK1 | |
| SCHEMBL149142 | 0.84 | PRMT5 (0.47) | PRMT5WDR77AAK1 | |
| SCHEMBL15077339 | 0.81 | PRMT5 (0.43) | PRMT5WDR77F2AAK1 | |
| SCHEMBL13718127 | 0.80 | PRMT5 (0.43) | PRMT5WDR77F2AAK1 | |
| SCHEMBL794482 | 0.80 | PRMT5 (0.43) | PRMT5WDR77F2AAK1 | |
| SCHEMBL793283 | 0.79 | ELANE (0.55) | ELANEF2PLAU | |
| SCHEMBL30450599 | 0.79 | PRMT5 (0.43) | PRMT5WDR77F2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616443-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | ELANE 3864/4885PRMT5 1471/4885WDR77 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.